膜杰作
Star Staining
分子别名（Synonym）
Podoplanin,PDPN,Gp36
表达区间及表达系统（Source）
Human Podoplanin, His Tag (PON-H52H3) is expressed from human 293 cells (HEK293). It contains AA Ala 23 - Leu 131 (Accession # Q86YL7-1).
Predicted N-terminus: Ala 23
Request for sequence
蛋白结构（Molecular Characterization）
This protein carries a polyhistidine tag at the C-terminus
The protein has a calculated MW of 13.0 kDa. The protein migrates as 19-21 kDa and 30-45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
内毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
纯度（Purity）
>90% as determined by SDS-PAGE.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
电泳（SDS-PAGE）
Human Podoplanin, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
活性（Bioactivity）-ELISA
Immobilized Human Podoplanin, His Tag (Cat. No. PON-H52H3) at 5 μg/mL (100 μL/well) can bind Human CLEC-2, Fc Tag (Cat. No. CL2-H5254) with a linear range of 0.313-5 μg/mL (QC tested).
Protocol
活性（Bioactivity）-SPR
Human Podoplanin, His Tag (Cat. No. PON-H52H3) immobilized on CM5 Chip can bind Human CLEC-2, Fc Tag (Cat. No. CL2-H5254) with an affinity constant of 0.495 μM as determined in a SPR assay (Biacore 8K) (QC tested).
Protocol
背景（Background）
Podoplanin (PDPN) is a type I transmembrane mucin-like glycoprotein expressed in the lymphatic endothelium. It is overexpressed in several solid tumors, such as squamous cell carcinoma, malignant mesothelioma, Kaposi sarcoma, angiosarcoma, testicular seminoma, and brain tumors. PDPN expression is associated with malignant progression, epithelial–mesenchymal transition, and metastasis.
